High-density lipoprotein: Gene-based approaches to the prevention of atherosclerosis

Annals of Medicine

Volumn 32, Issue 9, 2000, Pages 642-651

  Rong, J X ^a   Fisher, E A ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

Atherosclerosis; Gene therapy; High density lipoprotein metabolism

Indexed keywords

ABC TRANSPORTER; APOLIPOPROTEIN A1; CHOLESTEROL; HIGH DENSITY LIPOPROTEIN; PHOSPHATIDYLCHOLINE STEROL ACYLTRANSFERASE; SCAVENGER RECEPTOR;

ATHEROSCLEROSIS; CHOLESTEROL TRANSPORT; GENE THERAPY; HEART PROTECTION; HUMAN; LIPID OXIDATION; LIPOPROTEIN METABOLISM; PRIORITY JOURNAL; REVIEW;

EID: 0034511645     PISSN: 07853890     EISSN: None     Source Type: Journal    
DOI: 10.3109/07853890009002035     Document Type: Review

References (73)

1. High-density lipoprotein - The clinical implications of recent studies
2. Summary of the second report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II)
3. Current perspectives on statins
4. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S)
5. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels
6. Coronary heart disease prevalence and other clinical features in familial high-density lipoprotein deficiency
7. Isolated low HDL cholesterol as a risk factor for coronary heart disease mortality. A 21-year follow-up of 8000 men
8. High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies
9. Retroviral gene therapy in ApoE-deficient mice: ApoE expression in the artery wall reduces early foam cell lesion formation
10. Gene transfer and hepatic overexpression of the HDL receptor SR-BI reduces atherosclerosis in the cholesterol-fed LDL receptor-deficient mouse
11. Regression of atherosclerosis induced by liver-directed gene transfer of apolipoprotein A-I in mice
12. Rapid regression of atherosclerosis induced by liver-directed gene transfer of ApoE in ApoE-deficient mice
13. Complete atherosclerosis regression after human ApoE gene transfer in ApoE-deficient/nude mice
14. Somatic gene transfer of human ApoA-I inhibits atherosclerosis progression in mouse models
15. Structure and function of the plasma lipoproteins and their receptors
16. Plasma high-density lipoproteins and atherogenesis
17. High density lipoprotein and lipoprotein oxidation
18. The role of oxidized lipoproteins in atherogenesis
19. High density lipoproteins and coronary heart disease
20. Scavenger receptor BI (SR-BI) is up-regulated in adrenal gland in apolipoprotein A-I and hepatic lipase knock-out mice as a response to depletion of cholesterol stores. In vivo evidence that SR-BI is a functional high density lipoprotein receptor under feed-back control
21. The intrinsic factor-vitamin B12 receptor, cubilin, is a high-affinity apolipoprotein A-I receptor facilitating endocytosis of high-density lipoprotein
22. The ABCs of cholesterol efflux
23. Elevated high density lipoprotein cholesterol levels correlate with decreased apolipoprotein A-I and A-II fractional catabolic rate in women
24. Genes influencing HDL metabolism: New perspectives and implications for atherosclerosis prevention
25. Lack of apoA-I is not associated with increased susceptibility to atherosclerosis in mice
26. Inhibition of early atherogenesis in transgenic mice by human apolipoprotein AI
27. Apolipoprotein AI transgene corrects apolipoprotein E deficiency-induced atherosclerosis in mice
28. Human apolipoprotein A-I gene expression increases high density lipoprotein and suppresses atherosclerosis in the apolipoprotein E-deficient mouse
29. Inhibition of atherosclerosis development in cholesterol-fed human apolipoprotein A-I-transgenic rabbits
30. Cholesterol transport between cells and high-density lipoproteins
31. ApoA-II maintains HDL levels in part by inhibition of hepatic lipase. Studies In apoA-II and hepatic lipase double knockout mice
32. Cholesterol efflux, cholesterol esterification, and cholesteryl ester transfer by LpA-I and LpA-I/A-II in native plasma
33. A splice-junction mutation responsible for familial apolipoprotein A-II deficiency
34. Dramatically decreased high density lipoprotein cholesterol, increased remnant clearance, and insulin hypersensitivity in apolipoprotein A-II knockout mice suggest a complex role for apolipoprotein A-II in atherosclerosis susceptibility
35. Atherosclerosis in transgenic mice overexpressing apolipoprotein A-II
36. Studies on the in vivo and in vitro distribution of apolipoprotein A-IV in human plasma and lymph
37. Decreased HDL cholesterol levels but normal lipid absorption, growth, and feeding behavior in apolipoprotein A-IV knockout mice
38. Protection against atherogenesis in mice mediated by human apolipoprotein A-IV
39. The molecular pathology of lecithin: Cholesterol acyltransferase (LCAT) deficiency syndromes
40. Deficiency of lecithin: Cholesterol acyltransferase due to compound heterozygosity of two novel mutations (Gly33Arg and 30 bp ins) in the LCAT gene
41. Targeted disruption of the mouse lecithin: Cholesterol acyltransferase (LCAT) gene. Generation of a new animal model for human LCAT deficiency
42. High plasma HDL concentrations associated with enhanced atherosclerosis in transgenic mice overexpressing lecithin-cholesteryl acyltransferase
43. Overexpression of lecithin: Cholesterol acyltransferase in transgenic rabbits prevents diet-induced atherosclerosis
44. Cholesteryl ester transfer protein corrects dysfunctional high density lipoproteins and reduces aortic atherosclerosis in lecithin cholesterol acyltransferase transgenic mice
45. Protective effect of high density lipoprotein associated paraoxonase. Inhibition of the biological activity of minimally oxidized low density lipoprotein
46. Combined serum paraoxonase knockout/apolipoprotein E knockout mice exhibit increased lipoprotein oxidation and atherosclerosis
47. Mice lacking serum paraoxonase are susceptible to organo-phosphate toxicity and atherosclerosis
48. The Gln-Arg191 polymorphism of the human paraoxonase gene (HUMPONA) is not associated with the risk of coronary artery disease in Finns
49. Gln-Arg192 polymorphism of para-oxonase and coronary heart disease in type 2 diabetes
50. Increased high-density lipoprotein levels caused by a common cholesteryl-ester transfer protein gene mutation
51. Relationship of HDL and coronary heart disease to a common amino acid polymorphism in the cholesteryl ester transfer protein in men with and without hypertriglyceridemia
52. Phospholipid and cholesteryl ester transfer activities in plasma from 14 vertebrate species. Relation to atherogenesis susceptibility
53. Increased atherosclerosis in ApoE and LDL receptor gene knock-out mice as a result of human cholesteryl ester transfer protein transgene expression
54. A cholesteryl ester transfer protein inhibitor attenuates atherosclerosis in rabbits
55. Human plasma phospholipid transfer protein causes high density lipoprotein conversion
56. Targeted mutation of plasma phospholipid transfer protein gene markedly reduces high-density lipoprotein levels
57. Transgenic mice expressing human phospholipid transfer protein have increased HDL/non-HDL cholesterol ratio
58. Human plasma phospholipid transfer protein increases the antiatherogenic potential of high density lipoproteins in transgenic mice
59. Tangier disease is caused by mutations in the gene encoding ATP-binding cassette transporter 1
60. The gene encoding ATP-binding cassette transporter 1 is mutated in Tangier disease
61. Mutations in ABC1 in Tangier disease and familial high-density lipoprotein deficiency
62. Transport of lipids from golgi to plasma membrane is defective in tangier disease patients and Abc1-deficient mice
63. Dissociation of tissue uptake of cholesterol ester from that of apoprotein A-I of rat plasma high density lipoprotein: Selective delivery of cholesterol ester to liver, adrenal, and gonad
64. Identification of scavenger receptor SR-BI as a high density lipoprotein receptor
65. Association of polymorphisms at the SR-B gene locus with plasma lipid levels and body mass index in a white population
66. Influence of the high density lipoprotein receptor SR-BI on reproductive and cardiovascular pathophysiology
67. Increased LDL cholesterol and atherosclerosis in LDL receptor-deficient mice with attenuated expression of scavenger receptor B1
68. Decreased atherosclerosis in heterozygous low density lipo-protein receptor-deficient mice expressing the scavenger receptor BI transgene
69. Hepatic scavenger receptor BI promotes rapid clearance of high density lipoprotein free cholesterol and its transport into bile
70. Cubilin, the endocytic receptor for intrinsic factor-vitamin B(12) complex, mediates high-density lipoprotein holoparticle endocytosis
71. Adenovirus-mediated transfer of a gene encoding human apolipoprotein A-I into normal mice increases circulating high-density lipoprotein cholesterol
72. Potential gene therapy for lecithin-cholesterol acyltransferase (LCAT)-deficient and hypoalphalipoproteinemic patients with adenovirus-mediated transfer of human LCAT gene
73. Adenovirus mediated overexpression of human phospholipid transfer protein alters plasma HDL levels in mice